库罗斯生物科学公司的MagnetOs直接销售额增长了149%,在2024年前9个月达到5060万瑞士法郎. Kuros Biosciences experienced a 149% increase in direct MagnetOs sales, reaching CHF 50.6 million in the first nine months of 2024.
库罗斯生物科学公司报告称,MagnetOs的直接销售额激增了149%,在2024年前9个月达到5060万瑞士法郎. Kuros Biosciences reported a 149% surge in direct MagnetOs sales, reaching CHF 50.6 million in the first nine months of 2024. 2024年3月,Kuros医疗设备部分的总销售额上升到5 110万瑞士法郎。 Total sales in the Kuros Medical Devices segment rose to CHF 51.1 million in Q3 2024. 该公司首次超过现金流转平衡,实现了26%的EBITDA差值。 The company exceeded cash flow breakeven for the first time and achieved a 26% EBITDA margin. 库罗斯正在投资于Fusion项目,正在进行临床试验,并扩大了其在阿联,卡塔尔,澳大利亚和英国的市场存在. Kuros is investing in Project Fusion, with ongoing clinical trials, and has expanded its market presence in the UAE, Qatar, Australia, and the UK.